英矽智能与瑞博生物签署战略合作协议,端到端赋能RNA干扰和小核酸药物研发 (IMAGE) InSilico Medicine Caption 双方将在已经达成的基于英矽智能LifeStar 2实验室自动化、智能化和规模化能力的实验服务合作基础上,进一步结合英矽智能自有Pharma.AI 平台端到端研发能力,与瑞博生物深厚的小核酸药物研发积淀,全面提升小核酸药物研发效率。 Credit 英矽智能 Usage Restrictions None License Original content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.